adenine has been researched along with Co-infection in 52 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B." | 9.22 | Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. ( Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S, 2016) |
| "A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months." | 9.19 | Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. ( Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F, 2014) |
| " Treatment of chronic hepatitis C in patients coinfected with HIV is a complex problem associated with toxicities and drug interactions between HIV antiretrovirals and interferon and ribavirin." | 7.79 | Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. ( Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M, 2013) |
| "This study assessed HIV-hepatitis B virus (HBV) coinfection in southern Africa in terms of prevalence, viral characteristics, occult HBV, and the effect of lamivudine- versus tenofovir-containing first-line combination antiretroviral treatment (cART) on HBV-related outcomes." | 7.79 | HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. ( Botes, ME; Hamers, RL; Hoepelman, AI; Ive, P; Rinke de Wit, TF; Sigaloff, KC; Siwale, M; Stevens, WS; Wallis, CL; Zaaijer, HL, 2013) |
| "To evaluate the early virological response (EVR) to combined tenofovir-lamivudine or emtricitabine regimen in HBV/HIV-co-infected patients and the long-term efficacy of tenofovir." | 7.78 | Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012) |
| "Among 141 HIV-HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy." | 7.78 | Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012) |
| " His HBV is unresponsive to tenofovir/emtricitabine treatment demonstrated by persistent viremia despite lacking known resistance mutations and while having an undetectable HIV-1 viral load." | 7.77 | HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. ( Holodniy, M; Schirmer, P; Winters, M, 2011) |
| "Liver steatosis was retrospectively evaluated in all consecutive biopsies performed in the period 2000-2008 in HCV mono-infected and HIV-HCV co-infected patients." | 5.39 | Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir. ( Bisi, L; Borghi, V; Cossarizza, A; Manzini, L; Mussini, C, 2013) |
| "Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B." | 5.22 | Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. ( Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S, 2016) |
| " Using a computer-generated randomisation sequence, we randomly allocated antiretroviral-naive adult patients with HIV-1 and tuberculosis (aged ≥18 years with a plasma HIV RNA concentration of >1000 copies per mL) to receive raltegravir 400 mg twice a day, raltegravir 800 mg twice daily, or efavirenz 600 mg once daily plus tenofovir and lamivudine (1:1:1; stratified by country)." | 5.19 | Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. ( Arnold, V; Barcellos, NT; Brites, C; Chêne, G; De Castro, N; Delaugerre, C; Fagard, C; Grinsztejn, B; Madruga, JV; Molina, JM; Morgado, M; Patey, O; Pilotto, JH; Santini-Oliveira, M; Santos, BR; Veloso, VG; Vorsatz, C, 2014) |
| "A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months." | 5.19 | Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. ( Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F, 2014) |
| "The present report describes a case of a patient with hepatitis B virus (HBV)-human immunodeficiency virus (HIV) co-infection who was treated with tenofovir disoproxil (TDF)-based highly active antiretroviral therapy (HAART) and who achieved HBs antigen (Ag)/antibody (Ab) seroconversion." | 3.80 | An HBV-HIV co-infected patient treated with tenofovir-based therapy who achieved HBs antigen/antibody seroconversion. ( Abe, M; Hiasa, Y; Hirooka, M; Ikeda, Y; Koizumi, Y; Kumagi, T; Matsuura, B; Ochi, H; Tada, F; Takada, K; Tokumoto, Y; Watanabe, T, 2014) |
| " Treatment of chronic hepatitis C in patients coinfected with HIV is a complex problem associated with toxicities and drug interactions between HIV antiretrovirals and interferon and ribavirin." | 3.79 | Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. ( Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M, 2013) |
| " We also found that co-infection with HCV and treatment by the antiretrovirat drug Tenofovir are significantly associated with the decline in renal function among our patients [p=0." | 3.79 | [Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital]. ( Hassoun, G; Kedem, E; Mugrabi, F; Pollack, S; Shahar, E, 2013) |
| "This study assessed HIV-hepatitis B virus (HBV) coinfection in southern Africa in terms of prevalence, viral characteristics, occult HBV, and the effect of lamivudine- versus tenofovir-containing first-line combination antiretroviral treatment (cART) on HBV-related outcomes." | 3.79 | HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. ( Botes, ME; Hamers, RL; Hoepelman, AI; Ive, P; Rinke de Wit, TF; Sigaloff, KC; Siwale, M; Stevens, WS; Wallis, CL; Zaaijer, HL, 2013) |
| "To evaluate the early virological response (EVR) to combined tenofovir-lamivudine or emtricitabine regimen in HBV/HIV-co-infected patients and the long-term efficacy of tenofovir." | 3.78 | Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012) |
| "Among 141 HIV-HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy." | 3.78 | Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012) |
| "Data on the efficacy of lamivudine (LAM)-, tenofovir (TDF)- and emtricitabine (FTC)-based antiretroviral therapy (HAART) in HBV-HIV coinfection are limited." | 3.78 | Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. ( Grabmeier-Pfistershammer, K; Kosi, L; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Strassl, R, 2012) |
| " His HBV is unresponsive to tenofovir/emtricitabine treatment demonstrated by persistent viremia despite lacking known resistance mutations and while having an undetectable HIV-1 viral load." | 3.77 | HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. ( Holodniy, M; Schirmer, P; Winters, M, 2011) |
| "The pharmacokinetic data support coadministration of daclatasvir with atazanavir/ritonavir, efavirenz and/or tenofovir." | 2.78 | Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. ( Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M, 2013) |
| "Several drugs are available to treat hepatitis B." | 2.49 | Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. ( Bani-Sadr, F; de Vries-Sluijs, T; Dunn, D; Gilson, R; Jain, MK; Kuzushita, N; Mauss, S; Nüesch, R; Núñez, M; Peters, M; Pillay, D; Price, H; Reiberger, T; Stephan, C; Tan, L, 2013) |
| "Specialized treatment of CHB in pregnancy, coinfection, decompensated cirrhosis, and posttransplant is safe and effective." | 2.48 | New advances in chronic hepatitis B. ( Lee, WM; Tujios, SR, 2012) |
| "Those at risk for liver disease progression are usually treated with a combination of interferon (IFN) and ribavirin (RBV), which is not highly effective; it has low rates of sustained virologic response (SVR), especially for coinfected patients with HCV genotype 1 and those of African descent." | 2.48 | Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. ( Naggie, S; Sulkowski, MS, 2012) |
| "In areas where chronic hepatitis B virus infection is prevalent, acute hepatitis E virus superinfection on chronic hepatitis B virus infection occurs sporadically." | 1.48 | Seroclearance of hepatitis B surface antigen following hepatitis E exacerbation on chronic hepatitis E and B dual infection in a renal transplant recipient: a case report. ( Chiang, YJ; Chu, YD; Yeh, CS; Yeh, CT, 2018) |
| "Fanconi syndrome is a rare adverse effect of tenofovir disoproxil fumarate (TDF)." | 1.46 | Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient. ( Karris, MY, 2017) |
| "Dolutegravir (DTG) has been studied in three trials in HIV treatment-naive participants, showing noninferiority compared with raltegravir (RAL), and superiority compared with efavirenz and ritonavir-boosted darunavir." | 1.42 | Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. ( Almond, S; Arasteh, K; Brennan, C; Brinson, C; Cuffe, RL; Eron, J; Górgolas, M; Granier, C; Nichols, WG; Pappa, K; Rachlis, A; Raffi, F; Walmsley, S, 2015) |
| "Telbivudine seemed to be a candidate for exclusive anti-HBV therapy because it exerts no significant in vitro activity against HIV." | 1.39 | In vivo antiviral activity of telbivudine against HIV-1: a case report. ( Bonadies, G; Borgia, G; Borrelli, F; Buonomo, AR; Carleo, MA; Gentile, I; Portella, G, 2013) |
| "Liver steatosis was retrospectively evaluated in all consecutive biopsies performed in the period 2000-2008 in HCV mono-infected and HIV-HCV co-infected patients." | 1.39 | Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir. ( Bisi, L; Borghi, V; Cossarizza, A; Manzini, L; Mussini, C, 2013) |
| "TDF/emtricitabine was less likely to be associated with detectable HBV than other regimens, including TDF monotherapy (odds ratio, 2." | 1.39 | Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. ( Avihingsanon, A; Bowden, S; Dore, GJ; Finlayson, R; Hoy, JF; Lewin, SR; Littlejohn, M; Locarnini, S; Matthews, GV; Revill, PA; Ruxrungtham, K; Sasadeusz, J; Saulynas, M; Seaberg, EC; Thio, CL, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 50 (96.15) | 24.3611 |
| 2020's | 2 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Sarowar, A | 1 |
| Coffin, CS | 2 |
| Fung, S | 1 |
| Wong, A | 1 |
| Doucette, K | 1 |
| Truong, D | 1 |
| Conway, B | 1 |
| Haylock-Jacobs, S | 1 |
| Ramji, A | 1 |
| Hansen, BE | 2 |
| Janssen, HLA | 1 |
| Cooper, C | 1 |
| Huhn, GD | 1 |
| Ramgopal, M | 1 |
| Jain, MK | 2 |
| Hinestrosa, F | 1 |
| Asmuth, DM | 1 |
| Slim, J | 1 |
| Goldstein, D | 1 |
| Applin, S | 1 |
| Ryu, JH | 1 |
| Jiang, S | 1 |
| Cox, S | 1 |
| Das, M | 2 |
| Nguyen-Cleary, T | 1 |
| Piontkowsky, D | 1 |
| Guyer, B | 1 |
| Rossaro, L | 1 |
| Haubrich, RH | 1 |
| Karris, MY | 1 |
| Tartaglia, A | 1 |
| Ferrara, SM | 1 |
| Sica, S | 1 |
| Santantonio, T | 1 |
| Yeh, CT | 1 |
| Yeh, CS | 1 |
| Chu, YD | 1 |
| Chiang, YJ | 1 |
| MacBrayne, CE | 1 |
| Marks, KM | 1 |
| Fierer, DS | 1 |
| Naggie, S | 2 |
| Chung, RT | 1 |
| Hughes, MD | 1 |
| Kim, AY | 1 |
| Peters, MG | 1 |
| Brainard, DM | 1 |
| Seifert, SM | 1 |
| Castillo-Mancilla, JR | 1 |
| Bushman, LR | 1 |
| Anderson, PL | 1 |
| Kiser, JJ | 1 |
| Naing, C | 1 |
| Poovorawan, Y | 1 |
| Tong, KS | 1 |
| Tsai, WC | 1 |
| Hsu, WT | 1 |
| Liu, WD | 1 |
| Sun, HY | 1 |
| Chuang, YC | 1 |
| Huang, YS | 1 |
| Cheng, A | 2 |
| Lin, KY | 1 |
| Huang, YC | 1 |
| Chen, GJ | 1 |
| Huang, SH | 1 |
| Sheng, WH | 1 |
| Hsieh, SM | 1 |
| Hung, CC | 1 |
| Chang, SC | 1 |
| Childs, K | 1 |
| Joshi, D | 1 |
| Byrne, R | 1 |
| Bruce, M | 1 |
| Carey, I | 1 |
| Agarwal, K | 1 |
| Taylor, C | 1 |
| Antonucci, G | 1 |
| Mazzotta, F | 1 |
| Angeletti, C | 1 |
| Girardi, E | 1 |
| Puoti, M | 1 |
| De Stefano, G | 1 |
| Grossi, P | 1 |
| Petrosillo, N | 1 |
| Pagano, G | 1 |
| Cassola, G | 1 |
| Orani, A | 1 |
| Sagnelli, C | 2 |
| Armignacco, O | 1 |
| Sagnelli, E | 2 |
| Funk, EK | 1 |
| Shaffer, A | 1 |
| Shivakumar, B | 1 |
| Sneller, M | 1 |
| Polis, MA | 1 |
| Masur, H | 1 |
| Heytens, L | 1 |
| Nelson, A | 1 |
| Kwan, R | 1 |
| Kottilil, S | 1 |
| Kohli, A | 1 |
| Núñez, M | 2 |
| Mendes-Correa, MC | 1 |
| Shahar, E | 1 |
| Mugrabi, F | 1 |
| Kedem, E | 1 |
| Hassoun, G | 1 |
| Pollack, S | 1 |
| Price, H | 1 |
| Dunn, D | 1 |
| Pillay, D | 1 |
| Bani-Sadr, F | 1 |
| de Vries-Sluijs, T | 1 |
| Kuzushita, N | 1 |
| Mauss, S | 1 |
| Nüesch, R | 1 |
| Peters, M | 1 |
| Reiberger, T | 2 |
| Stephan, C | 1 |
| Tan, L | 1 |
| Gilson, R | 1 |
| Hamers, RL | 1 |
| Zaaijer, HL | 2 |
| Wallis, CL | 1 |
| Siwale, M | 1 |
| Ive, P | 1 |
| Botes, ME | 1 |
| Sigaloff, KC | 1 |
| Hoepelman, AI | 1 |
| Stevens, WS | 1 |
| Rinke de Wit, TF | 1 |
| Soriano, V | 1 |
| Poveda, E | 1 |
| Vispo, E | 1 |
| Barreiro, P | 1 |
| Pradat, P | 1 |
| Le Pogam, MA | 1 |
| Okon, JB | 1 |
| Trolliet, P | 1 |
| Miailhes, P | 2 |
| Brochier, C | 1 |
| Maynard, M | 1 |
| Bailly, F | 1 |
| Zoulim, F | 5 |
| Cotte, L | 1 |
| Bifano, M | 1 |
| Hwang, C | 1 |
| Oosterhuis, B | 1 |
| Hartstra, J | 1 |
| Grasela, D | 1 |
| Tiessen, R | 1 |
| Velinova-Donga, M | 1 |
| Kandoussi, H | 1 |
| Sevinsky, H | 1 |
| Bertz, R | 1 |
| Gentile, I | 1 |
| Bonadies, G | 1 |
| Carleo, MA | 1 |
| Buonomo, AR | 1 |
| Borrelli, F | 1 |
| Portella, G | 1 |
| Borgia, G | 1 |
| Hafkin, JS | 1 |
| Osborn, MK | 1 |
| Localio, AR | 1 |
| Amorosa, VK | 1 |
| Kostman, JR | 1 |
| Stern, JJ | 1 |
| De La Torre, P | 1 |
| Mounzer, K | 1 |
| Frank, I | 1 |
| Gross, R | 1 |
| Chang, KM | 1 |
| Lo Re, V | 1 |
| Boyd, A | 4 |
| Maylin, S | 4 |
| Gozlan, J | 2 |
| Delaugerre, C | 5 |
| Simon, F | 3 |
| Girard, PM | 4 |
| Lacombe, K | 4 |
| Kang, M | 1 |
| Hollabaugh, K | 1 |
| Pham, V | 1 |
| Koletar, SL | 1 |
| Wu, K | 1 |
| Smurzynski, M | 1 |
| Aberg, JA | 1 |
| Grinsztejn, B | 1 |
| De Castro, N | 1 |
| Arnold, V | 1 |
| Veloso, VG | 1 |
| Morgado, M | 1 |
| Pilotto, JH | 1 |
| Brites, C | 1 |
| Madruga, JV | 1 |
| Barcellos, NT | 1 |
| Santos, BR | 1 |
| Vorsatz, C | 1 |
| Fagard, C | 1 |
| Santini-Oliveira, M | 1 |
| Patey, O | 1 |
| Chêne, G | 1 |
| Molina, JM | 1 |
| Peytavin, G | 3 |
| Pisaturo, M | 1 |
| Martini, S | 1 |
| Filippini, P | 1 |
| Coppola, N | 1 |
| Maynard-Muet, M | 1 |
| Lebossé, F | 1 |
| Carrat, F | 1 |
| Bouix, C | 1 |
| Lascoux-Combe, C | 1 |
| Sogni, P | 1 |
| Rey, D | 1 |
| Barthe, Y | 1 |
| Pol, S | 1 |
| Cacoub, P | 1 |
| Piroth, L | 1 |
| Watanabe, T | 1 |
| Tokumoto, Y | 1 |
| Hirooka, M | 1 |
| Koizumi, Y | 1 |
| Tada, F | 1 |
| Ochi, H | 1 |
| Abe, M | 1 |
| Kumagi, T | 1 |
| Ikeda, Y | 1 |
| Matsuura, B | 1 |
| Takada, K | 1 |
| Hiasa, Y | 1 |
| Gürtler, LG | 1 |
| Sabo, JP | 1 |
| Kort, J | 1 |
| Ballow, C | 1 |
| Haschke, M | 1 |
| Battegay, M | 1 |
| Fuhr, R | 1 |
| Girlich, B | 1 |
| Schobelock, M | 1 |
| Feifel, U | 1 |
| Lang, B | 1 |
| Li, Y | 1 |
| Elgadi, M | 1 |
| Mweemba, A | 1 |
| Zanolini, A | 1 |
| Mulenga, L | 1 |
| Emge, D | 1 |
| Chi, BH | 1 |
| Wandeler, G | 1 |
| Vinikoor, MJ | 1 |
| James, G | 1 |
| Sidhu, P | 1 |
| Raza, M | 1 |
| Raffi, F | 1 |
| Rachlis, A | 1 |
| Brinson, C | 2 |
| Arasteh, K | 1 |
| Górgolas, M | 1 |
| Brennan, C | 1 |
| Pappa, K | 1 |
| Almond, S | 1 |
| Granier, C | 1 |
| Nichols, WG | 1 |
| Cuffe, RL | 1 |
| Eron, J | 1 |
| Walmsley, S | 1 |
| Marszalek, RM | 1 |
| Bae-Harboe, YS | 1 |
| Mahalingam, M | 1 |
| Masterpol, K | 1 |
| Garcia, M | 1 |
| Le Moal, G | 1 |
| Godet, C | 1 |
| Beraud, G | 1 |
| Chagneau-Derrode, C | 1 |
| Roblot, F | 1 |
| Gallant, J | 1 |
| Brunetta, J | 1 |
| Crofoot, G | 1 |
| Benson, P | 1 |
| Mills, A | 1 |
| Oka, S | 1 |
| Garner, W | 1 |
| Fordyce, M | 1 |
| McCallister, S | 1 |
| Cholongitas, E | 1 |
| Goulis, I | 1 |
| Antoniadis, N | 1 |
| Fouzas, I | 1 |
| Imvrios, G | 1 |
| Giakoustidis, D | 1 |
| Giouleme, O | 1 |
| Papanikolaou, V | 1 |
| Akriviadis, E | 1 |
| Vasiliadis, T | 1 |
| Schirmer, P | 1 |
| Winters, M | 1 |
| Holodniy, M | 1 |
| Lada, O | 2 |
| Gervais, A | 2 |
| Branger, M | 2 |
| Roquebert, B | 2 |
| Collin, G | 2 |
| Fraqueiro, G | 2 |
| Moucari, R | 2 |
| Hamet, G | 1 |
| Martinot-Peignoux, M | 3 |
| Matheron, S | 2 |
| Marcellin, P | 3 |
| Lavocat, F | 2 |
| Leclerc, L | 1 |
| Tujios, SR | 1 |
| Lee, WM | 1 |
| Sulkowski, MS | 1 |
| Tuaillon, E | 1 |
| Lozano, C | 1 |
| Kuster, N | 1 |
| Poinso, A | 1 |
| Kania, D | 1 |
| Nagot, N | 1 |
| Mondain, AM | 1 |
| Pageaux, GP | 1 |
| Ducos, J | 1 |
| Van de Perre, P | 1 |
| Reynes, J | 1 |
| Zoutendijk, R | 1 |
| de Vries-Sluijs, TE | 1 |
| Reijnders, JG | 1 |
| Mulder, JW | 1 |
| Kroon, FP | 1 |
| Richter, C | 1 |
| van der Eijk, AA | 1 |
| Sonneveld, MJ | 1 |
| de Man, RA | 1 |
| van der Ende, ME | 1 |
| Janssen, HL | 1 |
| Kim, JH | 1 |
| Psevdos, G | 1 |
| Sharp, V | 1 |
| Mikulska, M | 1 |
| Taramasso, L | 1 |
| Giacobbe, DR | 1 |
| Caligiuri, P | 1 |
| Bruzzone, B | 1 |
| Di Biagio, A | 1 |
| Viscoli, C | 1 |
| Naranbhai, V | 1 |
| Abdool Karim, SS | 1 |
| Altfeld, M | 1 |
| Samsunder, N | 1 |
| Durgiah, R | 1 |
| Sibeko, S | 1 |
| Abdool Karim, Q | 1 |
| Carr, WH | 1 |
| Kosi, L | 1 |
| Payer, BA | 1 |
| Grabmeier-Pfistershammer, K | 1 |
| Strassl, R | 1 |
| Rieger, A | 1 |
| Peck-Radosavljevic, M | 1 |
| Borghi, V | 1 |
| Bisi, L | 1 |
| Manzini, L | 1 |
| Cossarizza, A | 1 |
| Mussini, C | 1 |
| Fung, SK | 1 |
| Ma, MM | 1 |
| Matthews, GV | 1 |
| Seaberg, EC | 1 |
| Avihingsanon, A | 1 |
| Bowden, S | 1 |
| Dore, GJ | 1 |
| Lewin, SR | 1 |
| Sasadeusz, J | 1 |
| Revill, PA | 1 |
| Littlejohn, M | 1 |
| Hoy, JF | 1 |
| Finlayson, R | 1 |
| Ruxrungtham, K | 1 |
| Saulynas, M | 1 |
| Locarnini, S | 1 |
| Thio, CL | 1 |
| Bagnard, G | 1 |
| Lapalus, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamid[NCT02707601] | Phase 3 | 150 participants (Actual) | Interventional | 2016-04-01 | Completed | ||
| Liver Fibrosis in Zambian HIV-HBV Co-infected Patients: a Long-term Prospective Cohort Study[NCT02344680] | 303 participants (Actual) | Observational | 2015-10-31 | Active, not recruiting | |||
| Phase II Open-label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuber[NCT00822315] | Phase 2 | 155 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Multi-center Study Evaluating Persistence of Hepatitis B Virus Replication, Long-term Prognostic Indicators and Their Clinical Relevance in Patients Co-infected With the Human Immunodeficiency Virus and Chronic Hepatitis B[NCT02889094] | 152 participants (Actual) | Observational | 2016-10-31 | Active, not recruiting | |||
| Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994] | 275 participants (Actual) | Observational [Patient Registry] | 2018-02-06 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02707601)
Timeframe: Up to 32 weeks plus 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF (Co-administration: Week 8 to Week 20) | 62.5 |
| F/R/TAF + LDV/SOF (Co-administration: Week 8 to Week 20) | 69.4 |
| E/C/F/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV Week 12) | 83.8 |
| F/R/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV to Week 12) | 79.7 |
Sustained Virologic Response (SVR12) was defined as HCV RNA < the lower limit of quantitation (LLOQ) at 12 weeks after stopping LDV/SOF treatment. (NCT02707601)
Timeframe: HCV Posttreatment Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF | 98.6 |
| F/R/TAF + LDV/SOF | 95.8 |
SVR4 was defined as HCV RNA < LLOQ at 4 weeks after stopping LDV/SOF treatment. (NCT02707601)
Timeframe: HCV Posttreatment Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF | 98.6 |
| F/R/TAF + LDV/SOF | 98.6 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL 24 weeks after start of the F/TAF-based regimen were analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02707601)
Timeframe: 24 weeks after start of HIV treatment
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF | 1.4 |
| F/R/TAF + LDV/SOF | 1.4 |
7 reviews available for adenine and Co-infection
| Article | Year |
|---|---|
Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.
Topics: Adenine; Adult; Aged; Antiviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B; Hepatitis B | 2018 |
Viral hepatitis and HIV: update and management.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combina | 2013 |
Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
Topics: Adenine; Anti-HIV Agents; Coinfection; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Organ | 2013 |
Hepatitis B in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B Vaccine | 2013 |
Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
Topics: Adenine; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Guanine; Hepacivirus; | 2014 |
New advances in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Coinfection; Disease Progression; Drug Resistance, Viral; Female; Guanine | 2012 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease | 2012 |
8 trials available for adenine and Co-infection
| Article | Year |
|---|---|
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Topics: Adenine; Adult; Aged; Alanine; Benzimidazoles; Coinfection; Drug Combinations; Drug Resistance, Vira | 2020 |
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Fluorenes; Hepatit | 2018 |
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; | 2013 |
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agen | 2014 |
Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
Topics: Adenine; Adult; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Genotype | 2014 |
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinf | 2014 |
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Topics: Adenine; Adult; Alkynes; Aminoisobutyric Acids; Anti-HIV Agents; Antiretroviral Therapy, Highly Acti | 2014 |
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Coinfection; Drug Combinations; Drug Substitution; Em | 2016 |
37 other studies available for adenine and Co-infection
| Article | Year |
|---|---|
Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
Topics: Adenine; Alanine; Alanine Transaminase; Anti-Retroviral Agents; Canada; Cholesterol; Coinfection; He | 2022 |
Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
Topics: Adenine; Alanine; Anti-HIV Agents; Coinfection; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infectio | 2017 |
Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Hepatitis B, | 2017 |
Seroclearance of hepatitis B surface antigen following hepatitis E exacerbation on chronic hepatitis E and B dual infection in a renal transplant recipient: a case report.
Topics: Adenine; Coinfection; Disease Progression; DNA, Viral; Female; Graft Rejection; Hepatitis B Surface | 2018 |
Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection.
Topics: Adenine; Adult; Anti-Retroviral Agents; Coinfection; Female; Hepatitis B; HIV Infections; Humans; Ma | 2019 |
Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Coinfection; Deoxycytidine; DNA, Viral; Drug | 2013 |
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Coinfection; Cross-Sectional Studies; Deoxycytidine; Emtrici | 2013 |
Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Com | 2013 |
[Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital].
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis C; | 2013 |
HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection; | 2013 |
Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis B, Chro | 2013 |
In vivo antiviral activity of telbivudine against HIV-1: a case report.
Topics: Acute Disease; Adenine; Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis B | 2013 |
Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection; | 2014 |
Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2015 |
Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.
Topics: Adenine; Adult; Antibodies, Viral; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymp | 2014 |
An HBV-HIV co-infected patient treated with tenofovir-based therapy who achieved HBs antigen/antibody seroconversion.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Hepatitis | 2014 |
Effect of antiretroviral HIV therapy on hepatitis B virus replication and pathogenicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Deoxycytidine; Emtrici | 2014 |
Chronic hepatitis B virus coinfection is associated with renal impairment among Zambian HIV-infected adults.
Topics: Adenine; Adolescent; Adult; Africa; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate | 2014 |
First report of successful clearance of hepatitis B and D coinfection with tenofovir monotherapy.
Topics: Adenine; Adult; Coinfection; Hepatitis B; Hepatitis D; Humans; Male; Organophosphonates; Reverse Tra | 2015 |
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinic | 2015 |
Painless penile papule.
Topics: Adenine; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biops | 2015 |
First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
Topics: Absorptiometry, Photon; Adenine; Alanine; Coinfection; Dose-Response Relationship, Drug; Fanconi Syn | 2016 |
Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Guanin | 2016 |
HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance.
Topics: Adenine; Antiviral Agents; Coinfection; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Hepati | 2011 |
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Dr | 2012 |
Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Coinfection; Female; Genotype; Hepatitis B; H | 2012 |
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cloning, Molecular; Coinfection; DNA, Viral; Drug Resistance, Vira | 2012 |
Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HI | 2012 |
Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
Topics: Adenine; Adult; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Drug Administra | 2012 |
Five-year review of HIV-hepatitis B virus (HBV) co-infected patients in a New York City AIDS center.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Female; Hepatitis B; Hepatitis B e Antigens; HIV Infec | 2012 |
Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
Topics: Adenine; Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus | 2012 |
Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.
Topics: Adenine; Adult; Anti-HIV Agents; Avian Proteins; Case-Control Studies; Coinfection; Cytokines; Disea | 2012 |
Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Deoxycytid | 2012 |
Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Dideoxynucleosides; Fatty Liver; Female; Genotype; Hep | 2013 |
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.
Topics: Adenine; Allied Health Personnel; Antibodies, Viral; Antiviral Agents; Canada; Coinfection; Drug Res | 2012 |
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Australia; Coinfectio | 2013 |
Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Female; Genotype; Hepatitis B e A | 2013 |